Senol Tonyali1, Hakan Bahadir Haberal2, Emrullah Sogutdelen2. 1. Department of Urology, Turkiye Yuksek Ihtisas Training and Research Hospital, Hacettepe University School of Medicine, Ankara, Turkey. 2. Department of Urology, Hacettepe University School of Medicine, Ankara, Turkey.
Abstract
OBJECTIVES: Among males, prostate cancer (PCa) is the most common cancer in Europe and the second most common cancer worldwide, especially in those aged > 70 years. With the advent of novel alternative treatments, survival in patients with advanced PCa has increased. PCa is now considered a chronic disease. Survival is an important endpoint in advanced PCa, as is quality of life (QoL). The effects of the disease and its treatment on patient health-related QoL must be taken into account when selecting the most appropriate treatment options. The present literature review aimed to provide an overview of metastatic castration-resistant prostate cancer treatment modalities, with an emphasis on side effect profiles and general health-related QoL. METHODS: PubMed was searched using the keywords metastatic castration-resistant prostate cancer, docetaxel, cabazitaxel, enzalutamide, abiraterone acetate, and QoL. CONCLUSION: Based on the studies reviewed herein, abiraterone acetate and enzalutamide provide favorable outcomes, in terms of hematological adverse events. As enzalutamide and abiraterone acetate can be taken orally, they might have a positive effect on patient QoL.
OBJECTIVES: Among males, prostate cancer (PCa) is the most common cancer in Europe and the second most common cancer worldwide, especially in those aged > 70 years. With the advent of novel alternative treatments, survival in patients with advanced PCa has increased. PCa is now considered a chronic disease. Survival is an important endpoint in advanced PCa, as is quality of life (QoL). The effects of the disease and its treatment on patient health-related QoL must be taken into account when selecting the most appropriate treatment options. The present literature review aimed to provide an overview of metastatic castration-resistant prostate cancer treatment modalities, with an emphasis on side effect profiles and general health-related QoL. METHODS: PubMed was searched using the keywords metastatic castration-resistant prostate cancer, docetaxel, cabazitaxel, enzalutamide, abiraterone acetate, and QoL. CONCLUSION: Based on the studies reviewed herein, abiraterone acetate and enzalutamide provide favorable outcomes, in terms of hematological adverse events. As enzalutamide and abiraterone acetate can be taken orally, they might have a positive effect on patient QoL.
Entities:
Keywords:
Abiraterone acetate; Cabazitaxel; Castration resistant prostate cancer; Docetaxel; Enzalutamide; Quality of life
Authors: Amit Bahl; Susan Masson; Zafar Malik; Alison J Birtle; Santhanam Sundar; Rob J Jones; Nicholas D James; Malcolm D Mason; Satish Kumar; David Bottomley; Anna Lydon; Simon Chowdhury; James Wylie; Johann S de Bono Journal: BJU Int Date: 2015-06-16 Impact factor: 5.588
Authors: Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono Journal: N Engl J Med Date: 2012-08-15 Impact factor: 91.245
Authors: William Kevin Kelly; Susan Halabi; Michael Carducci; Daniel George; John F Mahoney; Walter M Stadler; Michael Morris; Philip Kantoff; J Paul Monk; Ellen Kaplan; Nicholas J Vogelzang; Eric J Small Journal: J Clin Oncol Date: 2012-03-26 Impact factor: 44.544
Authors: Tian Zhang; Mallika S Dhawan; Patrick Healy; Daniel J George; Michael R Harrison; Jorge Oldan; Bennett Chin; Andrew J Armstrong Journal: Clin Genitourin Cancer Date: 2015-01-24 Impact factor: 2.872
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: M T King; D S J Costa; N K Aaronson; J E Brazier; D F Cella; P M Fayers; P Grimison; M Janda; G Kemmler; R Norman; A S Pickard; D Rowen; G Velikova; T A Young; R Viney Journal: Qual Life Res Date: 2016-01-20 Impact factor: 4.147
Authors: Daniel Castellano; Luis M Antón Aparicio; Emilio Esteban; Alfredo Sánchez-Hernández; Jose Ramón Germà; Norberto Batista; Pablo Maroto; Begoña Pérez-Valderrama; Raquel Luque; María José Méndez-Vidal Journal: Expert Opin Drug Saf Date: 2014-07-07 Impact factor: 4.250
Authors: Lillian Y Lai; Mary K Oerline; Samuel R Kaufman; Lindsey A Herrel; Ted A Skolarus; Stacie B Dusetzina; Chad Ellimoottil; Vahakn B Shahinian; Brent K Hollenbeck; Megan E V Caram Journal: Urology Date: 2021-12-01 Impact factor: 2.649
Authors: Thomas Grochtdreis; Hans-Helmut König; Alexander Dobruschkin; Gunhild von Amsberg; Judith Dams Journal: PLoS One Date: 2018-12-05 Impact factor: 3.240
Authors: María Jesús Núñez-Iglesias; Silvia Novío; Carlota García; Elena Pérez-Muñuzuri; Pilar Soengas; Elena Cartea; Pablo Velasco; Manuel Freire-Garabal Journal: Int J Mol Sci Date: 2019-10-09 Impact factor: 5.923
Authors: Doo Yong Chung; Dong Hyuk Kang; Jong Won Kim; Do Kyung Kim; Joo Yong Lee; Chang Hee Hong; Kang Su Cho Journal: Cancers (Basel) Date: 2019-12-18 Impact factor: 6.639
Authors: Igor Tsaur; Anita Thomas; Michelle Monecke; Marion Zugelder; Jochen Rutz; Timothy Grein; Sebastian Maxeiner; Hui Xie; Felix K-H Chun; Florian Rothweiler; Jindrich Cinatl; Martin Michaelis; Axel Haferkamp; Roman A Blaheta Journal: Cancers (Basel) Date: 2022-06-24 Impact factor: 6.575
Authors: Brent K Hollenbeck; Mary Oerline; Samuel R Kaufman; Megan E V Caram; Stacie B Dusetzina; Andy M Ryan; Vahakn B Shahinian Journal: Urology Date: 2020-10-16 Impact factor: 2.649